• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Blue­bird’s gene ther­a­py shows promise in keep­ing lethal Loren­zo’s Oil dis­ease in check

8 years ago
R&D
Cell/Gene Tx

Armed with a $47M round, Gates-backed Vis­ter­ra aims at a PhI­Ib flu drug study

8 years ago
Financing
Startups

Faster, prici­er and of­ten worth­less: Study slams reg­u­la­tors for wave of ques­tion­able can­cer drug OKs

8 years ago
Pharma

Rhythm Phar­ma IPO goes over the top, snags $120M in lat­est sign the biotech win­dow is wide open

8 years ago
Financing

Con­gress fires an­oth­er sal­vo at Al­ler­gan’s Mo­hawk deal; AI out­fit rais­es $60M for dis­cov­ery ef­fort

8 years ago
News Briefing

FDA of­fers sur­prise OK for My­lan’s Co­pax­one knock­offs, slam­ming Te­va

8 years ago
Pharma

What fail­ure? Cataba­sis shares soar af­ter ex­ecs tout open-la­bel da­ta, PhI­II plans

8 years ago
R&D

Backed by Big Phar­ma VCs, Palleon ramps up a new ap­proach to im­muno-on­col­o­gy with a $48M start­up round

8 years ago
Financing
Startups

Fol­low­ing FDA de­ba­cle in ’09, Mo­tif lines up a new shot at ap­proval for an­tibi­ot­ic iclaprim

8 years ago
R&D

Am­i­cus’ lat­est pos­i­tive up­date on Pompe drug hints at ac­cel­er­at­ed ap­proval pitch

8 years ago
R&D

Am­gen-part­nered Im­mat­ics bags a $58M round to fund its first clin­i­cal steps on new T-cell tech for can­cer

8 years ago
Financing
Pharma

Am­gen comes up with $1.5B pack­age to part­ner with Cy­tomX on a pre­clin­i­cal Pro­body ap­proach to can­cer

8 years ago
Pharma

Dear Kite: With 2300% up­side, we blazed an amaz­ing trail

8 years ago
Biotech Voices

Pa­tients of­ten de­mand ex­per­i­men­tal drugs that prove in­ef­fec­tive — re­port

8 years ago
Pharma

Hot on heels of a pos­i­tive PhI­II, Abl­ynx files $150M IPO; Shire sues Al­ler­gan over dry eye drug ri­val­ry

8 years ago
News Briefing

Shov­ing Re­genxbio aside, Ul­tragenyx’s Emil Kakkis clos­es Di­men­sion buy­out deal with 400% pre­mi­um

8 years ago
Deals

Push­ing the pos­i­tive in p=0.05, Red­Hill says it’s ready for a piv­otal IBD test

8 years ago
R&D

On a roll, Rigel flags a pos­i­tive PhII for its lead, late-stage drug fos­ta­ma­tinib

8 years ago
R&D

Cel­gene joins the heavy­weight part­ner club col­lab­o­rat­ing with Nim­bus

8 years ago
Pharma

Re­searchers go af­ter the Holy Grail in flu re­search with the first big study for a uni­ver­sal jab

8 years ago
R&D

Top sci­en­tists and BD ex­ecs craft Cul­li­nan, a $150 mil­lion R&D port­fo­lio shop fo­cused on can­cer

8 years ago
People
Financing

Top trend #4: We’re com­ing to a tip­ping point on can­cer R&D, and it may not be pret­ty

8 years ago
R&D

Rigel surges as FDA waives pan­el; Trou­bled En­do­cyte looks for come­back fol­low­ing $12M li­cens­ing deal; Seat­tle ...

8 years ago
News Briefing

Sam Kulka­rni takes the helm at CRISPR Ther­a­peu­tics as found­ing CEO steps down

8 years ago
People
R&D
First page Previous page 1079108010811082108310841085 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.